NetworkNewsBreaks

FridayFeb 21, 2020 3:07 pm

NetworkNewsBreaks – Jerrick Media Holdings Inc. (JMDA) Receives Valuation by Zacks Small-Cap Research

Jerrick Media Holdings (OTCQB: JMDA), a holding company that gives technology products the resources and opportunities to make ideas a reality, was recently covered by Zacks Small-Cap Research. Zacks provided a final estimated valuation for the company of $13 per share by 2021, calculated using a combination of valuation metrics (http://nnw.fm/AB5jI). An article discussing the company reads, “Looking at Jerrick’s balance sheet, Zacks noted that the company ended the third quarter with $167,000 in cash reserves, $7.3 million in debt and a negative $8.1 million in working capital. ‘However, with the current capital raise, this will change drastically,’ stated the report,…

Continue Reading

FridayFeb 21, 2020 2:16 pm

NetworkNewsBreaks – HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) Targets Cannabinoid Extract Industry

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) is a hemp-biomass cultivation, extraction, formulation and refining entity that utilizes its trademarked Delta Reclaiming System technologies to limit CBD waste. A recent article discussing the company reads, “HTC Extraction Systems’ working relationships with other cannabinoid industry players further shore up its revenues possibilities. Most recently, the Canadian company closed its acquisition of a California-based company in the United States. The recently acquired Kase Farma Inc. is authorized to work with hemp cultivation, extraction, refining, formulation and business operations in the world’s largest cannabinoid market (http://nnw.fm/GtDz2), and HTC Extraction will reap the experience of…

Continue Reading

FridayFeb 21, 2020 2:09 pm

NetworkNewsBreaks – MCTC Holdings Inc. (MCTC) Provides Improved CBD-Infusion Method for Single-Serving Coffee Manufacturers

MCTC Holdings (OTC: MCTC), a research and development company deploying new extraction and infusion technologies for the cannabinoid and hemp industries, recently announced production of its new Hemp You Can Feel(TM) Coffee Infusions tablets and powders that enable food and beverage manufacturers to efficiently infuse their products. An article discussing the company reads, “MCTC’s Hemp You Can Feel(TM) Coffee Infusions are available either as a tablet containing cannabinoid infusions that can be added to coffee pods on a customer-customized basis, or as a cannabinoid powder for manufacturers with automated capabilities. . . .‘We are now offering single-serving coffee manufacturers a…

Continue Reading

FridayFeb 21, 2020 1:20 pm

NetworkNewsBreaks – Village Farms International, Inc. (NASDAQ: VFF) Featured in ROTH Equity Research Report

Village Farms International (NASDAQ: VFF) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “The Canadian cannabis market has been impacted by supply limitations, regulatory headwinds, and a thriving black market which we believe will persist through 1H20. We expect near-term exposure to weak Canadian wholesale pricing, but VFF's low-cost operations is built to survive commoditization; we expect high-cost LP production failures inevitable. Despite VFF brands gaining share at key provinces, continuing price pressure will impact VFF's top-line through 1H20. We are lowering 19/20 estimates and PT to $16.00, while maintaining our…

Continue Reading

FridayFeb 21, 2020 1:16 pm

NetworkNewsBreaks – eGain Corp. (NASDAQ: EGAN) Featured in ROTH Equity Research Report

eGain (NASDAQ: EGAN) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “EGAN's 2QF20 results were good, with revenues moderately above our forecast and adjusted operating income sharply above (at $2.6M versus our breakeven estimate). Updated F2020 guidance is mixed, seeing revenues at the lower-end of its prior guidance, but PF EPS is seen well above the prior guidance. Given good overall results in 1HF20, at odds with its recent severe valuation pressure, we reiterate our Buy rating and $15.00 price target.” To request access to the full report, visit http://nnw.fm/DXCr3 About…

Continue Reading

FridayFeb 21, 2020 1:12 pm

NetworkNewsBreaks – Pixelworks, Inc. (NASDAQ: PXLW) Featured in ROTH Equity Research Report

Pixelworks (NASDAQ: PXLW) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “We believe PXLW represents a differentiated investment opportunity in video display processing capabilities. Results in the quarter were in-line with expectations reflecting near-term demand weakness in projector and video delivery, with guidance below seasonal reflecting on-going inventory impact macro uncertainty. We are nonetheless very optimistic on the mobile revenue opportunity across both Iris smartphone ramp and TrueCut licensing. We expect other segments to recover in the mid-CY20 timeframe driving growth for the overall company. We maintain our Buy rating.” To…

Continue Reading

FridayFeb 21, 2020 12:35 pm

NetworkNewsBreaks – Arcus Biosciences, Inc. (NYSE: RCUS) Featured in Mizuho Securities Research Report

Arcus Biosciences (NYSE: RCUS) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “RCUS is trading up >20% today, which we believe is a result of the focus on TIGIT coming from RHHBY's (not covered) analyst meeting yesterday which highlighted the advancement of tiragolimab into Phase III (SKYSCRAPER-02) and discussion of its role as a novel immune checkpoint. RCUS is developing an anti-TIGIT mAb, AB154, which is currently in Phase II clinical studies, and we expect data disclosure in 4Q20 from this program. Our recent ‘Top of Mind’ note for RCUS…

Continue Reading

FridayFeb 21, 2020 12:31 pm

NetworkNewsBreaks – Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) Featured in Mizuho Securities Research Report

Xeris Pharmaceuticals (NASDAQ: XERS) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “We are lowering our 12-month price target to $18 from $22 and reaffirming our Buy rating on Xeris following its capital raise, completed on 2/11/20. The company issued 9 million shares, upsized from 6 mil, at $4.15 per share, raising approximately $37.4 mil prior to fees. We believe this should satisfy the company's capital requirements through 2H21, and expect another capital raise of $60 mil may be required to get Xeris to breakeven, which we continue to forecast…

Continue Reading

FridayFeb 21, 2020 11:38 am

NetworkNewsBreaks – DPW Holdings, Inc.’s (NYSE: DPW) Gresham Worldwide Defense Business Awarded $1.4M Purchase Order from Leading Defense and Aerospace Customer

DPW Holdings (NYSE: DPW), a diversified holding company, today announced that its global defense business, Gresham Worldwide, Inc., has received a $1.4 million order from a leading defense and aerospace customer of its wholly owned subsidiary Enertec Systems 2001, Ltd. According to the update, after receiving a $2.9 million order in 2019 to develop a unique and complex testing system, Enertec, an Israel-based leading defense and aerospace designer and manufacturer of advanced multi-purpose electronic systems, recently received an additional $1.4 million follow-up order related to the testing system. Enertec management believes the customer has the potential to order over $10…

Continue Reading

FridayFeb 21, 2020 11:33 am

NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Another Exemplary Addition to its Board

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced that its Board of Directors has unanimously appointed Dan Handley, M.S., Ph.D., to the Board. According to the update, Dr. Handley serves as a professor and the director of the Clinical and Translational Genome Research Institute of Southern California University of Health Sciences. Dr. Handley previously was the chief scientific officer of the Clinical and Translational Genome Research Institute, a Florida 501(c)3 non-profit corporation. “Predictive Oncology is once again very…

Continue Reading